Key Takeaways
- The TGA Compliance Principles 2026 and 2027 (in force from 1 January 2026 to 31 December 2027) name "therapeutic goods used in cosmetic procedures" as one of 12 priority focus areas, making dermal fillers and anti-wrinkle injectables a stated enforcement target for the full two-year window.
- Two regulators police cosmetic injectables: the TGA under the Therapeutic Goods Act 1989 (importing and advertising the medicine) and AHPRA under the National Law (the practitioner's conduct). A single import or social-media post can trigger both.
- In May 2026 the TGA issued 5 infringement notices totalling $19,800 to a Victorian AHPRA-registered nurse ($7,920) and a Victorian individual ($11,880) for unlawfully importing unapproved cosmetic injectables.
- The TGA issued a further 11 infringement notices totalling $43,560 to 6 individuals, 3 of them AHPRA-registered practitioners, for importing unapproved or counterfeit injectables and, in one case, unlawfully advertising botulinum toxin on social media.
- Botulinum toxin type A is a prescription-only medicine, and advertising a prescription-only medicine directly to the public is prohibited under the Therapeutic Goods Act. Importing goods not on the Australian Register of Therapeutic Goods without the required approval is unlawful, and counterfeit importation is unlawful in every circumstance.
- The TGA is explicitly targeting digital channels, including social media, influencers and online marketplaces, and reviews its focus areas quarterly.
- Infringement notices are the visible layer only: the TGA can also issue direction or prevention notices, accept enforceable undertakings, or pursue civil or criminal proceedings.
The TGA has made cosmetic injectables a formal enforcement priority for 2026 and 2027, and it is already acting on it. Since releasing its new Compliance Principles the regulator has issued infringement notices worth tens of thousands of dollars to nurses and individuals for illegally importing unapproved injectables and advertising botulinum toxin online. For a clinic, the message is that both the product and its marketing are now actively policed.
What are the TGA's 2026-27 compliance priorities?
In February 2026 the TGA released its Compliance Principles for 2026 and 2027, setting out how it will approach compliance and enforcement across the import, export, manufacture, supply and advertising of therapeutic goods. The framework runs on five core principles: safeguarding therapeutic goods, educate to empower, protect those most at risk, leverage digital capability, and strengthen enforcement. It is supported by priority focus areas that the regulator reviews quarterly, so it can respond to emerging risks without waiting for the next two-year cycle.
Twelve priority focus areas were current to 31 March 2026, and item 11 is "therapeutic goods used in cosmetic procedures", a category the Compliance Principles page describes as covering dermal fillers, anti-wrinkle injectables and other therapeutic goods administered in cosmetic settings. The practical effect for an injecting clinic is that non-compliance is no longer likely to be dealt with by education alone. Professor Anthony Lawler, head of the TGA, framed the approach as taking "firm, proportionate action when the rules are broken or ignored". Cosmetic injectables sit squarely inside that stated intent for the next two years.
Why do two regulators police cosmetic injectables?
This is what makes cosmetic injectables higher-stakes than ordinary practice marketing: the same conduct can breach two separate regimes. The TGA regulates the medicine itself under the Therapeutic Goods Act 1989, so importing an unapproved injectable or advertising a prescription-only injectable to the public is a therapeutic-goods offence. AHPRA and the National Boards regulate the practitioner under the National Law, so the same act can also be a professional-conduct matter that puts a registration at risk.
The two regimes are complementary, not alternatives. A nurse who imports unapproved filler and posts a promotion for it can face a TGA infringement notice for the import and the advertising, and an AHPRA notification about the same conduct. The AHPRA cosmetic procedure and advertising guidelines set the professional rules a clinic must follow, including the experience threshold for injecting nurses and the ban on testimonials and price advertising. This article covers the other half: what the TGA is enforcing and how it is acting on it in 2026.
What enforcement action has the TGA taken in 2026?
The priority is not theoretical. Within the same period as the Compliance Principles, the TGA issued two sets of infringement notices that show exactly what it is targeting and who is exposed.
| Action (2026) | Who | Notices and total | Alleged conduct |
|---|---|---|---|
| Paid May 2026 | A Victorian AHPRA-registered nurse and a Victorian individual | 5 notices, $19,800 | Unlawfully importing unapproved pre-filled cosmetic injectables (hyaluronic acid, poly-L-lactic acid, lidocaine); the individual also imported unapproved tranexamic acid |
| 2026 | 6 individuals, including 3 AHPRA-registered practitioners | 11 notices, $43,560 | Importing unapproved and, in one case, counterfeit injectables; a NSW individual also unlawfully advertised botulinum toxin on social media |
In the first matter, the nurse was issued two notices totalling $7,920 and the individual three totalling $11,880, all for importing unapproved goods that had not been assessed by the TGA for quality, safety and efficacy. In the second matter, one Victorian practitioner allegedly imported counterfeit cosmetic injectables of unknown composition, and a NSW-based individual advertised botulinum toxin, a prescription-only medicine, on a social-media platform. These sit alongside earlier corporate action noted in our AHPRA cosmetic compliance guide, where TGA infringement notices against a body corporate reached $106,560. The pattern is consistent: importation without approval and advertising to the public are the two behaviours drawing notices.
What is actually unlawful: importing and advertising injectables?
Two distinct prohibitions catch cosmetic clinics, and both are worth stating plainly because the breaches are easy to commit without intending harm.
The first is importation of unapproved goods. Therapeutic goods that are not entered in the Australian Register of Therapeutic Goods have not been assessed for quality, safety and efficacy. Importing them without an approval or authority is unlawful. The Personal Importation Scheme allows individuals to bring in certain goods for personal use if the legislative conditions are met, but a clinic sourcing filler or toxin outside the approved supply chain does not meet those conditions, and importing counterfeit product is unlawful in every case.
The second is advertising a prescription-only medicine to the public. Botulinum toxin type A is a prescription-only medicine, and the Therapeutic Goods Act prohibits advertising prescription-only medicines directly to consumers because it can create inappropriate demand and undermine the relationship between a patient and their prescriber. In practice that means a clinic cannot name the medicine, use its brand or nicknames, or promote it by price or offer. The TGA has been explicit that it is watching digital channels, so a promotional post, an influencer collaboration or an online-marketplace listing is exactly the kind of conduct the priority is designed to catch.
Are AHPRA-registered nurses being targeted?
Yes, and this is the detail a clinic manager should not miss. Of the enforcement action described above, one matter involved an AHPRA-registered nurse and another involved three AHPRA-registered practitioners among the six individuals. Registration is not a shield against TGA action, and a TGA infringement can become the trigger for a separate AHPRA process.
For an injecting clinic that employs or contracts nurses, the exposure runs both ways. If a practitioner sources product outside the approved channel or runs their own social-media promotion, the clinic can inherit the reputational and regulatory fallout, and the practitioner can face a mandatory notification if their conduct places patients at risk. The same direction of travel applies to prescribing: the TGA and AHPRA have both moved against remote and questionnaire-only models, which our telehealth and online prescribing guide covers in detail. Verifying where your product comes from and who controls your marketing is now a governance question, not a marketing one.
How can a clinic stay off the TGA's radar?
Treat this as a short governance project with an owner and a deadline. The priorities:
- Verify your supply chain. Confirm every injectable you hold is on the ARTG and was obtained through an approved supplier. Do not import product directly, and never source counterfeit or grey-market stock.
- Audit your advertising. Sweep your website, Instagram, TikTok, Facebook and Google listings for medicine names, brand names, nicknames, prices, package deals and before-and-after imagery for injectables, and remove them. Most breaches are posted by marketing staff, not clinicians, so brief whoever runs your social media.
- Control influencer content. Do not gift or pay for posts that promote your injectables, and do not repost an influencer's review. Testimonials about a regulated health service are separately prohibited under the National Law.
- Separate the medicine from the service. You can describe a consultation-led cosmetic service in general terms, but you cannot advertise the prescription-only medicine. Rewrite copy that names or implies a specific injectable.
- Check practitioner conduct. Make clear to injectors that personal importation and personal promotion of prescription-only medicines are grounds for both TGA and AHPRA action, and keep evidence that each injector meets the AHPRA experience and training requirements.
- Know your reporting duties. If you become aware that another practitioner is importing or advertising unlawfully in a way that risks patient safety, consider whether the mandatory notification threshold is met, and report suspected non-compliance to the TGA.
Frequently Asked Questions
Is the TGA actually enforcing cosmetic injectable rules in 2026?
Yes. The TGA named therapeutic goods used in cosmetic procedures a priority focus area under its Compliance Principles 2026 and 2027, and it has issued infringement notices in 2026, including 5 notices totalling $19,800 for unlawful importation and 11 notices totalling $43,560 to six individuals for importing unapproved or counterfeit injectables and advertising botulinum toxin online.
Is it legal to advertise Botox or anti-wrinkle injections in Australia?
No. Botulinum toxin type A is a prescription-only medicine, and advertising prescription-only medicines directly to the public is prohibited under the Therapeutic Goods Act 1989. You cannot name the brand, use nicknames such as "tox", or promote injectables by price or offer, including on social media. You can describe a consultation-led cosmetic service only in general, non-product terms.
Can a registered nurse be penalised by the TGA over cosmetic injectables?
Yes. The TGA has issued infringement notices to AHPRA-registered nurses in 2026 for unlawfully importing unapproved cosmetic injectables. Registration does not exempt a practitioner from the Therapeutic Goods Act, and a TGA infringement can also lead to a separate AHPRA notification about the practitioner's conduct.
What is the difference between the TGA and AHPRA rules on cosmetic injectables?
The TGA regulates the medicine under the Therapeutic Goods Act, covering how injectables are imported, supplied and advertised. AHPRA regulates the practitioner under the National Law, covering experience, consultation and professional conduct. The same act, such as importing unapproved filler and promoting it online, can breach both regimes at once.
What penalties can the TGA impose for cosmetic injectable breaches?
The TGA can issue infringement notices, which in recent 2026 matters have ranged from thousands to tens of thousands of dollars per matter, and against a body corporate have reached $106,560. It can also issue direction or prevention notices, accept enforceable undertakings, or pursue civil or criminal proceedings for serious or repeated non-compliance.
Does the TGA monitor social media and influencers?
Yes. The TGA's 2026-27 approach explicitly targets digital channels, including social media, influencers and online marketplaces. Its enforcement has included action against an individual who advertised botulinum toxin on a social-media platform, so clinic and influencer posts promoting prescription-only injectables are a direct enforcement risk.
Part of
AHPRA & Registration